NewTimeSpace News: NetEase, Inc. (09999.HK) announced that the Company has elected to become a dual-primary listed issuer on The Stock Exchange of Hong Kong Limited with effect from 30 June 2026, and the stock marker “S” will be removed from its stock short name simultaneously. The Exchange previously determined that the majority of trading in the Company’s listed securities has permanently migrated to the Hong Kong market. The Company has obtained waivers from the Exchange in respect of the adoption of U.S. GAAP, continuing connected transactions under contractual arrangements and the calculation of the minimum exercise price for share options.
NewTimeSpace News: KING'S STONE (01943.HK) plans to issue up to 200 million shares by placement, with estimated net proceeds of HKD 107.75 million.
NewTimeSpace News: PuraPharm Corporation Limited (01498.HK) announced that Professor Tsui Lap-chee has resigned as Independent Non-executive Director, as well as member of the Audit Committee, Remuneration Committee and Nomination Committee, effective 25 June 2026. Having served as Independent Non-executive Director for over nine years, Professor Tsui tendered his resignation to support board refreshment and succession planning.
Jiu Rong Holdings (2358.HK) announced that its indirect wholly-owned subsidiary Zhejiang Jiurong Intelligent Technology entered into an asset transaction contract with independent third party Guangzhou Yingfu Technology to sell five panel display intelligent production lines and related auxiliary and testing equipment for RMB6.05 million (inclusive of tax) via public listing on the Hangzhou Property Exchange; the unaudited net book value of the assets was approximately RMB2.109 million as of December 31, 2025, with an estimated pre-tax gain of approximately RMB3.941 million, and net proceeds of approximately RMB5.354 million to be mainly used to repay outstanding loans secured by the mortgage and pledge; the Disposal is expected to complete before early July 2026 and constitutes a discloseable transaction as applicable percentage ratios exceed 5% but are below 25%; the Board believes the sale aligns with the Group's strategic shift to a light-asset operating model, enabling realization of residual value from idle assets while reducing maintenance costs and alleviating liquidity pressure.
Hengrui Medicine (1276.HK) announced three simultaneous developments on June 25, 2026: its subsidiary Shanghai Shengdi's adebrelimab injection was approved for a new NSCLC perioperative indication, becoming the first domestic PD-L1 inhibitor approved for this setting, with Phase III data showing a 53.8% MPR rate, 74.8% 2-year EFS rate and a 48% reduction in recurrence/progression/death risk, with cumulative R&D investment of approximately RMB1.225 billion; subsidiary Chengdu Shengdi's cyclosporine eye drops (IV) received marketing approval as China's first and only 0.1% anhydrous cyclosporine eye drop for dry eye, licensed from Novaliq with 17.6-fold improved bioavailability, with cumulative R&D investment of approximately RMB103 million; and HRS-4508 tablets were cleared for clinical trials in advanced solid tumors, with multiple Phase II trials underway covering breast and lung cancers, and cumulative R&D investment of approximately RMB82 million.
DT Capital (356.HK) announced it entered into a non-binding strategic cooperation memorandum with Laplace Lab Limited, the sole designated technology developer of decentralized prediction market platform SigMarket, to jointly explore decentralized prediction market technology in enterprise risk management, internal decision support and scenario analysis, including developing risk management analysis tools and AI-customized solutions; the work is limited to internal research and proof-of-concept, Laplace Lab is an independent third party, and the Board believes the cooperation will enhance internal risk management capabilities without materially affecting the Group's current year financial performance.
Henlius (2696.HK) announced that the European Commission approved serplulimab (Hansizhuang®/HETRONIFLY®) in combination with carboplatin and nab-paclitaxel for first-line treatment of adult patients with unresectable locally advanced or metastatic sqNSCLC, applicable across all EU member states and EEA countries; the approval was based on a randomized, double-blind, international multi-center Phase 3 study showing significant benefit and good safety, following EU GMP certification in December 2023 and a positive CHMP opinion in May 2026; serplulimab is now approved in China, the EU, UK and multiple Southeast Asian countries, with the global PD-1 mAb market reaching approximately USD50.871 billion in 2025.
Leads Biolabs (9887.HK) announced that its joint venture with Aditum Bio, Oblenio, completed an oversubscribed $62 million Series B financing led by Pfizer Ventures with participation from Deep Track Capital, GV and Aditum Bio, to significantly advance clinical development of LBL-051, a CD19/BCMA/CD3 tri-specific T-cell engager for severe autoimmune diseases; preclinical data presented at EULAR 2026 showed complete B cell and plasma cell clearance in non-human primates without CRS, and the Company founder Dr. Kang Xiaoqiang will join Oblenio's board as an observer, with the Company entitled to milestone payments and sales royalties as the original developer.
By the close of trading on Jun 25, 2026, HJ SCIENCE-B(06132.HK) saw a gain of 38.03% in its share price, closing at HKD 49. During the session, it reached an intraday high of HKD 50.5 and touched an intraday low of HKD 36.
June 25, 2026, MADISON HLDG(08057.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 57.9 million, decreased by 18.55% YoY
June 25, 2026, MI MING MART(08473.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 119.91 million, increased by 0.98% YoY
June 25, 2026, GC CONSTRUCTION(01489.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 259.59 million, decreased by 51.08% YoY
June 25, 2026, TAI CHEUNG HOLD(00088.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 27.9 million, decreased by 22.5% YoY
June 25, 2026, AEON CREDIT(00900.HK) released its Q1 Report for the period ended February 28, 2027, Total Revenue stood at HKD 451.4 million, increased by 8.89% YoY
June 25, 2026, UBA INVESTMENTS(00768.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 3.41 million, decreased by 32.35% YoY
June 25, 2026, EDVANCE INTL(01410.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 776.67 million, increased by 5.76% YoY
